NFL Biosciences SA (ALNFL.PA)
EUR 1.88
(-2.59%)
EUR 1.88
(-2.59%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 62.17 Thousand EUR | -25.32% |
| 2022 | 83.25 Thousand EUR | -2.06% |
| 2021 | 85 Thousand EUR | 0.01% |
| 2020 | 85 Thousand EUR | 0.0% |
| 2019 | - EUR | -100.0% |
| 2018 | 50 Thousand EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 53.35 Thousand EUR | -14.18% |
| 2023 Q4 | 62.17 Thousand EUR | -14.51% |
| 2023 FY | 62.17 Thousand EUR | -25.32% |
| 2023 Q2 | 72.72 Thousand EUR | -12.65% |
| 2022 FY | 83.25 Thousand EUR | -2.06% |
| 2022 Q4 | 83.25 Thousand EUR | -2.06% |
| 2022 Q2 | 85 Thousand EUR | 0.0% |
| 2021 FY | 85 Thousand EUR | 0.01% |
| 2021 Q2 | 289.83 Thousand EUR | 0.0% |
| 2020 FY | 85 Thousand EUR | 0.0% |
| 2019 FY | - EUR | -100.0% |
| 2018 FY | 50 Thousand EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | 98.166% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 99.888% |
| Adocia SA | 13.08 Million EUR | 99.525% |
| Aelis Farma SA | 4.03 Million EUR | 98.46% |
| Biophytis S.A. | 8.27 Million EUR | 99.248% |
| Advicenne S.A. | 17.42 Million EUR | 99.643% |
| genOway Société anonyme | 7.23 Million EUR | 99.14% |
| IntegraGen SA | 1.12 Million EUR | 94.472% |
| Medesis Pharma S.A. | 1.2 Million EUR | 94.819% |
| Neovacs S.A. | 650 Thousand EUR | 90.435% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 98.573% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | 97.712% |
| Sensorion SA | 2.86 Million EUR | 97.833% |
| Theranexus Société Anonyme | 3.64 Million EUR | 98.293% |
| TME Pharma N.V. | 1.16 Million EUR | 94.668% |
| Valbiotis SA | 6.87 Million EUR | 99.096% |
| TheraVet SA | 1.15 Million EUR | 94.64% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | 99.309% |
| argenx SE | 18.1 Million EUR | 99.657% |
| BioSenic S.A. | 28.16 Million EUR | 99.779% |
| Celyad Oncology SA | 902 Thousand EUR | 93.107% |
| DBV Technologies S.A. | 13.01 Million USD | 99.522% |
| Galapagos NV | 9.59 Million EUR | 99.352% |
| Genfit S.A. | 70.17 Million EUR | 99.911% |
| GeNeuro SA | 7.73 Million EUR | 99.196% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | 98.826% |
| Innate Pharma S.A. | 39.89 Million EUR | 99.844% |
| Inventiva S.A. | 37.4 Million EUR | 99.834% |
| MaaT Pharma SA | 14.07 Million EUR | 99.558% |
| MedinCell S.A. | 58.96 Million EUR | 99.895% |
| Nanobiotix S.A. | 50.56 Million EUR | 99.877% |
| Onward Medical N.V. | 16.87 Million EUR | 99.632% |
| Oryzon Genomics S.A. | 13.68 Million EUR | 99.546% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | 99.864% |
| Oxurion NV | 12.33 Million EUR | 99.496% |
| Pharming Group N.V. | 155.29 Million EUR | 99.96% |
| Poxel S.A. | 46.9 Million EUR | 99.867% |
| GenSight Biologics S.A. | 18.42 Million EUR | 99.663% |
| Transgene SA | 1.25 Million EUR | 95.054% |
| Financière de Tubize SA | 79.2 Million EUR | 99.921% |
| UCB SA | 3.03 Billion EUR | 99.998% |
| Valneva SE | 208.81 Million EUR | 99.97% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -63.616% |